Current Urology Reports

, Volume 9, Issue 5, pp 342–345 | Cite as

A 49-year-old Hispanic male with intraepithelial neoplasia and focal atypia

Challenging Case
  • 21 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Nam RK, Toi A, Klotz LH, et al.: Assessing individual risk for prostate cancer. J Clin Oncol 2007, 25:3582–3588.PubMedCrossRefGoogle Scholar
  2. 2.
    Loeb S, Roehl KA, Antenor JA, et al.: Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 2006, 67:316–320.PubMedCrossRefGoogle Scholar
  3. 3.
    Catalona WJ, Partin AW, Slawin KM, et al.: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998, 279:1542–1547.PubMedCrossRefGoogle Scholar
  4. 4.
    American Cancer Society: Cancer Facts and Figures for Hispanics/Latinos, 2006–2008. Atlanta, GA: American Cancer Society; 2008.Google Scholar
  5. 5.
    Benson MC, Whang IS, Pantuck A, et al.: Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992, 147:815–816.PubMedGoogle Scholar
  6. 6.
    Thompson IM, Ankerst DP, Chi C, et al.: Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006, 98:529–534.PubMedCrossRefGoogle Scholar
  7. 7.
    Fleshner NE, O’sullivan M, Fair WR: Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol 1997, 158:505–508; discussion 508–509.PubMedCrossRefGoogle Scholar
  8. 8.
    Catalona WJ, Beiser JA, Smith DS: Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies. J Urol 1997, 158:2162–2167.PubMedCrossRefGoogle Scholar
  9. 9.
    Keetch DW, McMurtry JM, Smith DS, et al.: Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies. J Urol 1996, 156:428–431.PubMedCrossRefGoogle Scholar
  10. 10.
    Meng MV, Shinohara K, Grossfeld GD: Significance of high-grade prostatic intraepithelial neoplasia on prostate biopsy. Urol Oncol 2003, 21:145–151.PubMedGoogle Scholar
  11. 11.
    Stewart CS, Leibovich BC, Weaver AL, Lieber MM: Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001, 166:86–91; discussion 91–82.PubMedCrossRefGoogle Scholar
  12. 12.
    Smith DS, Catalona WJ: Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 1994, 152:1163–1167.PubMedGoogle Scholar
  13. 13.
    Krejcarek SC, Chen MH, Renshaw AA, et al.: Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer. Urology 2007, 69:515–519.PubMedCrossRefGoogle Scholar
  14. 14.
    Barnard RJ: Prostate cancer prevention by nutritional means to alleviate metabolic syndrome. Am J Clin Nutr 2007, 86:889–893.Google Scholar
  15. 15.
    Thune I, Furberg AS: Physical activity and cancer risk: dose-response and cancer, all sites and site-specific. Med Sci Sports Exerc 2001, 33(6 Suppl):S530–S550; discussion S609–S510.PubMedGoogle Scholar
  16. 16.
    Bidoli E, Talamini R, Bosetti C, et al.: Macronutrients, fatty acids, cholesterol and prostate cancer risk. Ann Oncol 2005, 16:152–157.PubMedCrossRefGoogle Scholar
  17. 17.
    Stacewicz-Sapuntzakis M, Borthakur G, Burns JL, Bowen PE: Correlations of dietary patterns with prostate health. Mol Nutr Food Res 2008, 52:114–130.PubMedCrossRefGoogle Scholar
  18. 18.
    Koutros S, Cross AJ, Sandler DP, et al.: Meat and meat mutagens and risk of prostate cancer in the Agricultural Health Study. Cancer Epidemiol Biomarkers Prev 2008, 17:80–87.PubMedCrossRefGoogle Scholar
  19. 19.
    Syed DN, Khan N, Afaq F, Mukhtar H: Chemoprevention of prostate cancer through dietary agents: progress and promise. Cancer Epidemiol Biomarkers Prev 2007, 16:2193–2203.PubMedCrossRefGoogle Scholar
  20. 20.
    Thompson IM, Goodman PJ, Tangen CM, et al.: The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215–224.PubMedCrossRefGoogle Scholar
  21. 21.
    Lucia MS, Epstein JI, Goodman PJ, et al.: Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007, 99:1375–1383.PubMedCrossRefGoogle Scholar
  22. 22.
    Thompson IM, Chi C, Ankerst DP, et al.: Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006, 98:1128–1133.PubMedCrossRefGoogle Scholar
  23. 23.
    Fang J, Metter EJ, Landis P, et al.: Low levels of prostate specific antigen (PSA) predict the long term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 2001, 58:411–416.PubMedCrossRefGoogle Scholar
  24. 24.
    Loeb S, Roehl KA, Antenor JAV, et al.: Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 2006, 67:316–320.PubMedCrossRefGoogle Scholar
  25. 25.
    Raaijmakers R, Blijenberg BG, Finlay JA, et al.: Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. J Urol 2004, 171:2245–2249.PubMedCrossRefGoogle Scholar
  26. 26.
    Thompson IM, Goodman PJ, Tangen CM, et al.: The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215–224.PubMedCrossRefGoogle Scholar
  27. 27.
    Thompson IM, Ankerst DP, Chi C, et al.: Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Nat Cancer Inst 2006, 98:529–534.PubMedGoogle Scholar
  28. 28.
    Epstein JI, Herawi M: Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol 2006, 175:820–834.PubMedCrossRefGoogle Scholar
  29. 29.
    Lucia MS, Epstein JI, Goodman PJ, et al.: Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Nat Cancer Inst 2007, 99:1375–1383.PubMedCrossRefGoogle Scholar
  30. 30.
    Thompson IM, Goodman PJ, Tangen CM, et al.: The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215–224.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Department of UrologyUniversity of Miami, Miller School of MedicineMiamiUSA

Personalised recommendations